Pda Technical Report 82 Patched

"Low Endotoxin Recovery,"

PDA Technical Report No. 82 (TR 82), titled was published in March 2019 to provide critical guidance on the phenomenon of Low Endotoxin Recovery (LER).

Method Suitability

Traditional BET suitability (spike recovery at time zero) is not enough . TR-82 mandates time-dependent recovery studies to detect LER. pda technical report 82

1. No Safe Threshold: The report does not define what level of LER is "acceptable." Is 24-hour recovery enough? 48? This is left to the manufacturer’s risk assessment.
2. Recombinant Alternatives: TR 82 was published before the widespread availability of highly stable rFC assays. Some newer data suggests rFC may be less susceptible to LER than LAL, but TR 82 treats both as vulnerable.
3. Cost of Compliance: Running a 7-day, multi-temperature LER study for every formulation is expensive and resource-intensive. Many smaller companies ignore TR 82 until a regulatory citation occurs.

Key points from PDA Technical Report 82

• High Risk: IV injections, intrathecal drugs (low pyrogenic dose).
• Medium Risk: IM or SC injections.
• Low Risk: Topicals, orals (where endotoxin is irrelevant).
• Formulation Risk Factors: Presence of Polysorbate 80 > 0.01%, EDTA, citrate, or high pH (>8.0).

• A monoclonal antibody formulation with 0.02% polysorbate 80 showing 0% recovery after 24 hours.
• A small molecule IV formulation with EDTA showing 100% recovery if tested within 2 hours, but 20% recovery at 48 hours.

• Dilution (to break micelles)
• Heating (e.g., 70–75°C)
• Addition of detergents (e.g., polysorbate 20)
• Mechanical agitation (vortexing, sonication)

PDA Technical Report 82 is a comprehensive guide for evaluating sterile compounding facilities. Its significance extends beyond regulatory compliance, contributing to patient safety and industry best practices. The implications of TR 82 are far-reaching, requiring organizations to invest in facility design and construction, enhance quality control and quality assurance, provide training and education, and ensure regulatory preparedness. As the pharmaceutical and biotechnology industries continue to evolve, TR 82 will remain a critical resource for ensuring the quality and safety of sterile compounded products. "Low Endotoxin Recovery," PDA Technical Report No

A significant portion of the report addresses the risk of biofilm. No Safe Threshold: The report does not define